INM Key Statistics, Chart & Performance
The current stock price of INM is 1.25 USD. In the past month the price decreased by -4.58%. In the past year, price decreased by -71%.
INM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.35 | 1.03T | ||
| JNJ | JOHNSON & JOHNSON | 19.82 | 495.71B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.48B | ||
| PFE | PFIZER INC | 7.9 | 143.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.80B | ||
| ZTS | ZOETIS INC | 20.01 | 55.90B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.8 | 23.24B | ||
| VTRS | VIATRIS INC | 5.41 | 14.51B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.21 | 11.55B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.72B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About INM
Company Profile
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Company Info
INMED PHARMACEUTICALS INC
1445-885 West Georgia St.
Vancouver BRITISH COLUMBIA V6C1B4 CA
CEO: Eric Adams
Employees: 13
Phone: 16046697207
INMED PHARMACEUTICALS INC / INM FAQ
What does INMED PHARMACEUTICALS INC do?
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
What is the current price of INM stock?
The current stock price of INM is 1.25 USD. The price increased by 4.17% in the last trading session.
What is the dividend status of INMED PHARMACEUTICALS INC?
INM does not pay a dividend.
What is the ChartMill technical and fundamental rating of INM stock?
INM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for INM stock?
INMED PHARMACEUTICALS INC (INM) currently has 13 employees.
Can you provide the market cap for INMED PHARMACEUTICALS INC?
INMED PHARMACEUTICALS INC (INM) has a market capitalization of 3.50M USD. This makes INM a Nano Cap stock.
What is the ownership structure of INMED PHARMACEUTICALS INC (INM)?
You can find the ownership structure of INMED PHARMACEUTICALS INC (INM) on the Ownership tab.
INM Technical Analysis
INM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INM. While INM seems to be doing ok healthwise, there are quite some concerns on its profitability.
INM Financial Highlights
Over the last trailing twelve months INM reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS increased by 48.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.46% | ||
| ROE | -70.84% | ||
| Debt/Equity | 0 |